-
Baekje BGB-16673 clinical trial application based on the innovative PROTAC technology platform was accepted by CDE
Time of Update: 2021-12-09
FinishingrainbowToday, the latest announcement by CDE shows that the clinical trial application of BeiGene BTK protein degradation agent BGB-16673 film-coated tablets has been accepted .
This is BeiGene's first product under development based on its protein-degrading CDAC (innovative PROTAC) platform and entering the clinical stage.
-
LH-1802 Capsules of Lianhuan Pharmaceutical obtained the "Notice of Drug Clinical Trial Approval"
Time of Update: 2021-12-09
On November 9, Lianhuan Pharmaceutical issued an announcement stating that it had recently received the "Drug Clinical Trial Approval Notice" for LH-1802 capsules (specification: 0.
Recently, clinical trials of relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) have been carried out .
-
3 billion large varieties were looted, Guangzhou pharmaceutical companies are about to be approved
Time of Update: 2021-12-09
com, lansoprazole will be the TOP5 drug for peptic ulcer treatment in public medical institutions in China in 2020, with sales exceeding 3 billion yuan .
-
Potential curative therapy for hepatitis B has entered a critical development stage, and the virus can continue to be suppressed after the drug is stopped
Time of Update: 2021-12-09
Moreover, early clinical trial results showed that after 28 days of ATI-2173 medication, even if the medication is stopped, the patient's HBV DNA level can maintain a long time without rebound .
Reference materials:[1] Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV.
-
First-line treatment prolongs the lives of patients with biliary tract cancer. The combination of PD-L1 inhibitors is better than standard chemotherapy
Time of Update: 2021-12-09
On October 25, 2021, AstraZeneca announced that the blockbuster PD-L1 inhibitor durvalumab (durvalumab, English trade name: Imfinzi) was combined with chemotherapy for the first-line treatment of advanced biliary tract cancer ( BTC) patients reached the primary endpoint in a phase 3 clinical trial .
-
The latest procurement progress and clinical use proportions of 157 nationally sourced varieties are at a glance!
Time of Update: 2021-12-09
From December 20, 2020 to September 30, 2021, the procurement situation is as follows:Purchase quantity and amountThe total number of selected drugs purchased in the 12 alliance regions of the province is 470,964,800 pieces/piece/bag .
-
Genetron Health and NeoGenomics reached a strategic cooperation to help global oncology drug research and development
Time of Update: 2021-12-09
This cooperation, combined with the advantages of Xinjihao's global pharmaceutical services and clinical trials, and Genetron Health's experience in the localization of global innovative drugs, will help both parties to comprehensively improve their drug R&D support and service capabilities, and enable the company to better serve To meet the needs of global drug research and development and clinical projects .
-
The first patient was administered to the first patient in the clinical trial of the pioneering pharmaceutical industry's ALK-1 monoclonal antibody combined with Corning Jereh KN046 in the treatment of advanced or refractory solid tumors
Time of Update: 2021-12-09
ALK-1 monoclonal antibody combination therapy is in Taiwan, China The clinical trial data of the second-line treatment of advanced liver cancer showed that it has good safety and anti-tumor activity.
-
Saisheng Pharmaceutical's Miconazole Oral Patch Nomico® is officially launched commercially
Time of Update: 2021-12-09
Nomico® is a miconazole patch with a unique patented dosage form, which can be quickly released in the oral cavity and maintain a stable antibacterial concentration to treat oropharyngeal candidiasis, once a day, providing patients with a new convenient treatment option .
-
Bayer meets its rivals!
Time of Update: 2021-12-09
According to data from Mi Nei. com, in 2020, the total sales of nifedipine tablets in the terminals of Chinese public medical institutions and the terminals of physical pharmacies in Chinese cities will exceed 8 billion yuan, of which Bayer has the largest market share .
-
A new generation of anti-flu drugs!
Time of Update: 2021-12-09
According to information on Zhengxiang's official website, ZX-7101A is a new generation of oral anti-influenza drug independently developed by the company .
Retrieved Nov 1, 2021, from http:// The clinical trial application of Zhengxiang Medicine's new anti-influenza drug ZX-7101A was officially approved by NMPA.
-
After Zhong Suansui, can the 9-valent HPV vaccine recreate the richest man in China?
Time of Update: 2021-12-09
At present, the fastest domestic 9-valent HPV vaccine research and development progress is in clinical phase III, and there are 4 companies in this phase, namely Bowei Biotechnology, Wantai Biotechnology, Kangleweishi and Ruike Biotechnology, and vaccine companies before Phase III Although there are many, there is a high probability that they will miss the "first prize" .
-
Menarini receives FDA orphan drug designation for acute myeloid leukemia drug
Time of Update: 2021-12-09
gov number NCT03008187) is the first human phase I/II dose upgrade and cohort expansion trial of SEL24/MEN1703, and it was studied as a single agent for the treatment of patients with relapsed/refractory AML .
-
BeiGene introduced over 100 million U.S. dollars!
Time of Update: 2021-12-09
ArticleMedicine GuanlanRecently, the Chinese drug clinical trial registration and information disclosure platform showed that BeiGene has launched a phase 3 study of zanidatamab (ZW25) in China for the first-line treatment of advanced HER2-positive gastroesophageal adenocarcinoma .
-
The "three high" drugs are here for purchase!
Time of Update: 2021-12-09
On November 5th, the Henan Provincial Medical Insurance Bureau issued the "Announcement on the Procurement of Drug Alliance of the 13 Provinces (Cities, Districts, and Corps) of Henan, Mongolia, Jiangxi, Jiangxi, Guangdong, Guiyu, Yunnan, Shaanxi, Qingning, and Ningxin Corps (1)", announcing the "Relevant drugs are purchased in quantity .
-
Competition in the PI3K inhibitor market has increased
Time of Update: 2021-12-09
A few days ago, Incyte announced that the FDA has accepted a new generation of phosphatidylinositol 3-kinase delta (PI3K delta) inhibitor parsaclisib for the treatment of relapsed or refractory follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma New Drug Application (NDA) for Type 3 Non-Hodgkin’s Lymphoma (MCL) .
-
Sichuan pharmaceutical companies attack $12 billion star antineoplastic drug
Time of Update: 2021-12-09
According to data from Meinenet, the global sales of lenalidomide capsules in 2020 will exceed 12 billion U.
S. dollars; the terminal sales of public medical institutions in China will exceed 1 billion .
In 2020, the global sales of this product exceeded 12 billion U.
-
Kras/PD-1 combined first-line lung cancer debut
Time of Update: 2021-12-09
newsnewsToday Mirati announced some data from its Kras inhibitor adagrasib and Merck’s K drug combination in a 1b clinical trial called KRYSTAL-1 .
Kras inhibitors have a larger therapeutic window for patients with Kras variant tumors, so the combination with K drugs may be better tolerated .
-
For social anxiety!
Time of Update: 2021-12-09
Public information shows that PH94B is a potential "first-in-class", fast-acting neurosteroid drug candidate under development by VistaGen, and it has entered a phase 3 clinical study for the treatment of social anxiety disorder (SAD) worldwide .
-
How do post-collection pharmaceutical companies control R&D risks?
Time of Update: 2021-12-09
To this day, although the current two-invoice system and centralized procurement have promoted the urgency of enterprises for drug R&D and innovation, the requirements for drug R&D are also higher and the cost is greater, and the market environment is more demanding, so we need to use more A lot of wisdom to solve the problems faced at that time: how to evaluate the value of new drugs?
